Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
KYMR logo KYMR
Upturn stock ratingUpturn stock rating
KYMR logo

Kymera Therapeutics Inc (KYMR)

Upturn stock ratingUpturn stock rating
$43.64
Last Close (24-hour delay)
Profit since last BUY23.7%
upturn advisory
Consider higher Upturn Star rating
BUY since 40 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: KYMR (2-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Number of Analysts

rating

20 Analysts rated it

Highly popular stock, broad analyst coverage, trusted insights, strong investor interest.

1 Year Target Price $61

1 Year Target Price $61

Analysts Price Target For last 52 week
$61Target price
Low$19.45
Current$43.64
high$53.27

Analysis of Past Performance

Type Stock
Historic Profit 89.69%
Avg. Invested days 33
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 4.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 2.87B USD
Price to earnings Ratio -
1Y Target Price 61
Price to earnings Ratio -
1Y Target Price 61
Volume (30-day avg) 20
Beta 2.07
52 Weeks Range 19.45 - 53.27
Updated Date 06/30/2025
52 Weeks Range 19.45 - 53.27
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -3.11

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -336.77%

Management Effectiveness

Return on Assets (TTM) -19.47%
Return on Equity (TTM) -32.17%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 2496255340
Price to Sales(TTM) 48.79
Enterprise Value 2496255340
Price to Sales(TTM) 48.79
Enterprise Value to Revenue 42.39
Enterprise Value to EBITDA -9.49
Shares Outstanding 65119600
Shares Floating 41673919
Shares Outstanding 65119600
Shares Floating 41673919
Percent Insiders 2.69
Percent Institutions 111.66

Analyst Ratings

Rating 5
Target Price 61
Buy 3
Strong Buy 14
Buy 3
Strong Buy 14
Hold 3
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Kymera Therapeutics Inc

stock logo

Company Overview

overview logo History and Background

Kymera Therapeutics Inc. was founded in 2016. It is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins, pioneering targeted protein degradation (TPD).

business area logo Core Business Areas

  • Targeted Protein Degradation: Kymera's core business is the development of protein degraders that target specific proteins involved in disease pathways. They design heterobifunctional molecules that recruit E3 ligases to tag target proteins for degradation.
  • Drug Discovery and Development: Kymera engages in drug discovery, preclinical research, and clinical development, moving potential therapies from the laboratory to human trials.
  • Partnerships and Licensing: Kymera collaborates with other pharmaceutical companies to develop and commercialize its TPD technology, generating revenue through licensing agreements and milestone payments.

leadership logo Leadership and Structure

Nello Mainolfi, PhD, is the President and CEO. The company has a board of directors and a management team overseeing research, development, finance, and operations.

Top Products and Market Share

overview logo Key Offerings

  • KT-474 (SAR444229): A IRAK4 degrader being developed in collaboration with Sanofi. It is in clinical trials for hidradenitis suppurativa, atopic dermatitis and other inflammatory conditions. Market share data is not yet applicable as the product is still in clinical development. Competitors: Biogen, Janssen, Novartis.
  • KT-333: A STAT3 degrader in clinical trials for relapsed/refractory lymphomas and solid tumors. Market share data is not yet applicable as the product is still in clinical development. Competitors: Relay Therapeutics, Voronoi.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is highly competitive and focuses on developing new therapies for various diseases. Targeted protein degradation represents an emerging modality.

Positioning

Kymera is a leader in the TPD field, holding a strong intellectual property portfolio and advanced clinical programs. They have a first-mover advantage but face increasing competition.

Total Addressable Market (TAM)

The TAM for protein degradation therapies is potentially very large, estimated in the tens of billions of dollars, as it offers a novel approach to target previously undruggable proteins. Kymera is positioned to capture a significant portion of this market if their clinical programs are successful.

Upturn SWOT Analysis

Strengths

  • Pioneering TPD technology
  • Strong intellectual property
  • Experienced leadership team
  • Strategic partnerships (Sanofi, Vertex)
  • Advanced clinical programs

Weaknesses

  • High R&D costs
  • Clinical trial risks
  • Dependence on partnerships
  • Relatively small company size
  • Limited revenue stream

Opportunities

  • Expansion into new therapeutic areas
  • Development of new protein degraders
  • Increased adoption of TPD technology
  • Potential for breakthrough therapies
  • Partnerships with big pharma

Threats

  • Competition from other biopharmaceutical companies
  • Regulatory hurdles
  • Clinical trial failures
  • Economic downturns
  • Patent challenges

Competitors and Market Share

competitor logo Key Competitors

  • VRTX
  • MRTX
  • ARVN

Competitive Landscape

Kymera faces competition from established pharmaceutical companies and other emerging biotechnology companies developing TPD therapies or similar modalities. Their competitive advantage lies in their first-mover advantage, proprietary technology, and strategic partnerships.

Growth Trajectory and Initiatives

Historical Growth: Kymera's historical growth is characterized by rapid expansion of its research pipeline and increasing partnerships.

Future Projections: Future growth is projected to be driven by successful clinical trial outcomes and regulatory approvals of its lead drug candidates. Analyst estimates vary widely depending on the success of its clinical programs.

Recent Initiatives: Recent initiatives include the advancement of KT-474 and KT-333 into later-stage clinical trials, expanding research into new disease areas, and strengthening partnerships.

Summary

Kymera Therapeutics is a promising company in the emerging field of targeted protein degradation. The company has strong partnerships and a robust pipeline, but faces significant clinical and regulatory risks. Financial stability is heavily reliant on successful clinical trials and continued investment. It is important to watch the clinical trial results to understand how the company is performing.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Kymera Therapeutics Inc. Investor Relations
  • SEC Filings
  • Market Research Reports
  • Analyst Estimates

Disclaimers:

This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Kymera Therapeutics Inc

Exchange NASDAQ
Headquaters Watertown, MA, United States
IPO Launch date 2020-08-21
Co-Founder, President, CEO & Director Dr. Nello Mainolfi M.D., Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 208
Full time employees 208

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in allergic and atopic diseases; and TYK2 to treat autoimmune and inflammatory diseases. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside of the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.